menu

FDA D.I.S.C.O.: Rucaparib in Ovarian Cancer

Be part of the knowledge.
Register

We’re glad to see you’re enjoying ReachMD…
but how about a more personalized experience?

Register for free

FDA D.I.S.C.O.: Rucaparib in Ovarian Cancer

close
FDA D.I.S.C.O.: Rucaparib in Ovarian Cancer
RestartResume
Choose a format
Media formats available:
Details
Comments
  • Overview

    FDA medical oncologists discuss the agency’s accelerated approval of rucaparib for treatment of patients with deleterious BRCA mutation-associated advanced ovarian cancer who have been treated with two or more chemotherapies.

    Released May 17, 2017

Facebook Comments

Recommended
Details
Comments
  • Overview

    FDA medical oncologists discuss the agency’s accelerated approval of rucaparib for treatment of patients with deleterious BRCA mutation-associated advanced ovarian cancer who have been treated with two or more chemotherapies.

    Released May 17, 2017

Facebook Comments

LIVE ON REACHMD RADIOBack to live radio

Loading...

Programs 1/28/20